Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Study of Urine Volatile Organic Compounds for Disease Detection (TOBY ATLAS)

9 de noviembre de 2026 actualizado por: Toby, Inc.

TOBY ATLAS: A Multi-Site, Non-Interventional Study of Urinary Volatile Organic Compounds

The goal of this observational study is to develop and evaluate urine tests for detecting disease in adults. It will initially focus on prostate, bladder, and kidney cancer. Researchers will compare urine samples and medical records from people with and without these diseases to see whether the tests can detect them accurately. Participants may provide a urine sample during a routine visit. Study results will not be returned to participants or used in their care.

Descripción general del estudio

Estado

Aún no reclutando

Descripción detallada

TOBY ATLAS is a multi-center master protocol that supports the development and validation of urine-based tests for screening, diagnosis, and monitoring of multiple diseases. The study uses prospectively collected, residual, banked, and purchased urine samples, where permitted.

Researchers will analyze urine for volatile organic compounds using gas chromatography-mass spectrometry and develop models using samples with known disease status. Each model will be locked before it is evaluated using a separate set of blinded samples.

Disease status and available standard-of-care test results will be obtained from medical records. Researchers may also review records over time to identify later diagnoses or outcomes. Sites and diseases may be added as the study progresses.

Tipo de estudio

De observación

Inscripción (Estimado)

30000

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: TOBY ATLAS Study Team
  • Número de teléfono: 309-592-8898
  • Correo electrónico: info@toby.health

Copia de seguridad de contactos de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Adults with target diseases and comparison participants, including healthy volunteers and individuals with other diseases, benign conditions, or negative diagnostic work-ups. Participants are identified through routine care and other permitted specimen sources.

Descripción

Inclusion Criteria:

  • Age 50 years or older, or another age range set in the applicable disease specification (for example, 45 or older for colorectal cancer).
  • Informed consent, or eligibility under an exemption or waiver for waste, residual, banked, or purchased specimens.
  • Medical records available for the reference standard.
  • Meets the case or control definition and other inclusion criteria in at least one disease specification, or belongs to the Healthy Control Set.

Exclusion Criteria:

  • Any exclusion stated in the applicable disease specification.
  • Symptomatic urinary tract infection at collection, unless enrolled as a confounder control.
  • Current pregnancy, imprisonment, or inability to consent for oneself (consented route).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: CASE_CONTROL
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Target disease cases

Participants with a target disease established by the applicable reference standard, including participants assessed after treatment where specified.

Controls

Participants without the target disease for a given analysis, including healthy participants and participants with other diseases, benign conditions, or negative diagnostic work-ups.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Clinical performance of each locked assay
Periodo de tiempo: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.

Sensitivity and specificity at pre-specified thresholds, and area under the receiver operating characteristic curve, of each locked assay against the applicable reference standard in its intended-use population, using blinded validation specimens not used to develop that assay. Estimates will include 95% confidence intervals.

At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
Paired comparison with available standard-of-care tests
Periodo de tiempo: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.

Differences in sensitivity, specificity, and area under the receiver operating characteristic curve between each locked assay and each available standard-of-care test in the same participants, with 95% confidence intervals.

At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Assay performance by subgroup and signal origin
Periodo de tiempo: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.

Sensitivity, specificity, and area under the receiver operating characteristic curve across thresholds and by disease characteristics, populations, and control types, including stage, grade, and age; accuracy of signal-origin classification.

At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
Protocol-conforming specimens with final reference-standard classification
Periodo de tiempo: From specimen collection through reference-standard classification, including medical-record review at approximately 12 months where available.

Number of protocol-conforming urine specimens with final reference-standard classification, summarized by disease and control type.

From specimen collection through reference-standard classification, including medical-record review at approximately 12 months where available.

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Candidate assays advanced to validation
Periodo de tiempo: From study start through study completion, estimated up to 5 years

Number of candidate assays developed using the Development Pool that are locked and carried forward to a Validation Plan.

From study start through study completion, estimated up to 5 years
Exploratory prognostic and simulated clinical and economic outcomes
Periodo de tiempo: Up to 5 years after specimen collection, where follow-up is permitted and available

Where optional medical-record follow-up is available, compare progression, recurrence, treatment response, stage at diagnosis, procedures, health care use, and costs with blinded assay predictions. These are exploratory prognostic and simulated health-economic analyses; test results are not used in care.

Up to 5 years after specimen collection, where follow-up is permitted and available

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de enero de 2027

Finalización primaria (Estimado)

1 de enero de 2032

Finalización del estudio (Estimado)

1 de enero de 2032

Fechas de registro del estudio

Enviado por primera vez

4 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Publicado por primera vez (Actual)

12 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

There is currently no plan to make individual participant data available to other researchers.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir